Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04343170
Other study ID # ultrashort treatment of anemia
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 1, 2023
Est. completion date December 30, 2024

Study information

Verified date November 2023
Source Tanta University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Scoliosis is a condition in which there is curvature of the spine occurring in the lateral plane. It occurs in structural forms, characterized by a fixed curve, and "functional" forms, characterized by a flexible or correctable curve. By anatomic necessity, this lateral deviation is associated with vertebral rotation, such that when this deformity occurs in the thoracic spine, a chest wall deformity, or "rib hump," develops. Often there is a primary structural curve with an adjacent secondary compensatory curve. Most cases of structural scoliosis are idiopathic and have their onset in early adolescence. Females are affected more often than males, and their curvature is more likely to worsen. Lumbar fusion surgery is usually associated with massive blood loss. In clinical practice the surgeon might measure the visible peri-operative bleeding including intra- and post-operative drainage, but ignore blood component penetration into the tissues, residual blood in vertebral canal and loss due to haemolysis, which are also known as hidden blood loss. In patients with adolescent idiopathic scoliosis (AIS), surgical treatment involves a posterior approach with multi-segmental pedicle screw fixation. Although this procedure is generally considered safe with few surgical complications, there are considerable variations in fusion length, surgical time, and the extent of soft-tissue exposure. Consequently, perioperative blood loss can be substantial, and the use of intraoperative and postoperative RBC transfusions are frequently required. Patient blood management (PBM) is an evidence-based, multidisciplinary approach developed over the last 10 years focusing on improving patient outcomes as well as reducing the use of RBC transfusions. PBM includes several preventive measures to manage bleeding risks, reduce iatrogenic blood loss, and modify decision thresholds for the appropriate administration of blood therapy. All patients for elective surgery in whom blood loss is expected to be > 500 ml should have their hemoglobin checked pre-operatively and be investigated if they are found to be anemic. In the general population, anemia is defined as a hemoglobin less than 130 g. in men and less than 120g. in women by the WHO. It was proposed that the cut-off value/trigger be changed to hemoglobin more than 130 g for both men and women. Women with hemoglobin levels between 120 and 129 g. are not considered to be anemic according to the WHO definition, leaving them at a potential disadvantage when undergoing major surgery


Description:

44 Patients will be randomly classified into two equal groups each of 22 patients Group I: Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum) Group II: Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo. Either iron or placebo (0•9% saline) were given intravenously via a black infusion set from behind a screen to assure blinding of the patient by a person not involved in data capturing or data entering. Patient's vital signs will be monitored during and at least 15 min after drug application. Treatment will be given one day before the operation Measurements: 1. Demographic data 2. The number of RBC transfusions during the first 7 days. 3. Perioperative course of Hb, (reticulocyte count, reticulocyte Hb content). 4. The need of fresh frozen plasma units transfused in first 7 days 5. The need of platelets units transfused in first 7 days 6. Platelet count. 7. Total leucocyte counts. 8. International normalized ratio. 9. Serum creatinine. 10. C-reactive protein, 11. Calculated RBC loss (preoperative RBC mass minus RBC mass at postoperative fifth day plus transfused RBC mass) 12. Length of ICU stay. 13. Incidence of acute kidney injury 14. Infections requiring antibiotics


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 44
Est. completion date December 30, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 13 Years to 45 Years
Eligibility Inclusion Criteria: - patients with idiopathic adolescent scoliosis - patients with anemia (haemoglobin concentration (Hb) <12g/dL in women and Hb <13 g/dL in men) - patients with isolated iron deficiency (ferritin <100 mcg/L, no anemia) Exclusion Criteria: 1. Impairments, diseases (renal &/ hepatic) or language problems which do not allow the patient to fully understand the consequences of study participation 2. Known allergy against iron - carboxymaltose 3. Hemoglobin concentration (Hb) <90 g/L in both male and female)

Study Design


Intervention

Drug:
Placebo
Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
ferric carboxymaltose , a erythropoietin, vitamin B12, oral folic acid
Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous a erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)

Locations

Country Name City State
Egypt tarek Abdel Lattif Tanta

Sponsors (1)

Lead Sponsor Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary percentage of patients not required blood transfusion percentage of patients not required blood transfusion up to 7 days postoperative
Secondary the length in I.C.U the length in I.C.U by days during ICU stay period up to 7 days postoperative
Secondary the incidence of acute kidney injury number of patients developed acute kidney injury up to 7 days postoperative
Secondary incidence of infections requiring antibiotic treatment number of patients developed infections requiring antibiotic treatment up to 7 days postoperative
Secondary perioperative hemoglobin perioperative hemoglobin by gm up to 7 days postoperative
Secondary perioperative platelet perioperative platelet presented as platelet count per microliter of blood up to 7 days postoperative
Secondary perioperative leucocyte counts perioperative leucocyte counts presented as white blood cells per microliter up to 7 days postoperative
Secondary calculated Red blood cells loss calculated Red blood cells loss by ml up to 7 days postoperative
See also
  Status Clinical Trial Phase
Recruiting NCT06027801 - Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity N/A
Completed NCT02282553 - Gastric Capsule Examination for Iron Deficiency Anaemia N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting NCT04913649 - Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients Phase 4
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT01438645 - ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy N/A
Completed NCT01307007 - Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding Phase 2
Completed NCT00982007 - Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA) Phase 3
Completed NCT00198848 - Iron Supplementation Among Adolescent Girls in India N/A
Completed NCT01166451 - The Anemia Control Program: High or Low Iron Supplementation N/A
Recruiting NCT03893045 - A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects Phase 3
Recruiting NCT03817957 - Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency Phase 3
Completed NCT03819530 - Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study N/A
Completed NCT03618914 - Anemia and Inflammation
Completed NCT03940430 - Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students Phase 2/Phase 3
Withdrawn NCT03873584 - Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
Enrolling by invitation NCT03897673 - Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas N/A
Active, not recruiting NCT04778072 - A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects N/A
Completed NCT03237065 - Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Phase 3
Completed NCT05153278 - IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department